vs

Side-by-side financial comparison of NEOGENOMICS INC (NEO) and TRICO BANCSHARES (TCBK). Click either name above to swap in a different company.

NEOGENOMICS INC is the larger business by last-quarter revenue ($186.7M vs $109.4M, roughly 1.7× TRICO BANCSHARES ). TRICO BANCSHARES runs the higher net margin — 251.6% vs -57.9%, a 309.5% gap on every dollar of revenue. On growth, NEOGENOMICS INC posted the faster year-over-year revenue change (11.1% vs 9.0%). Over the past eight quarters, NEOGENOMICS INC's revenue compounded faster (6.5% CAGR vs 5.4%).

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.

NEO vs TCBK — Head-to-Head

Bigger by revenue
NEO
NEO
1.7× larger
NEO
$186.7M
$109.4M
TCBK
Growing faster (revenue YoY)
NEO
NEO
+2.1% gap
NEO
11.1%
9.0%
TCBK
Higher net margin
TCBK
TCBK
309.5% more per $
TCBK
251.6%
-57.9%
NEO
Faster 2-yr revenue CAGR
NEO
NEO
Annualised
NEO
6.5%
5.4%
TCBK

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
NEO
NEO
TCBK
TCBK
Revenue
$186.7M
$109.4M
Net Profit
$-108.0M
$33.6M
Gross Margin
43.3%
Operating Margin
46.9%
42.6%
Net Margin
-57.9%
251.6%
Revenue YoY
11.1%
9.0%
Net Profit YoY
42.0%
15.8%
EPS (diluted)
$-0.13
$1.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEO
NEO
TCBK
TCBK
Q1 26
$186.7M
Q4 25
$190.2M
$109.4M
Q3 25
$187.8M
$107.6M
Q2 25
$181.3M
$103.6M
Q1 25
$168.0M
$98.6M
Q4 24
$172.0M
$100.4M
Q3 24
$167.8M
$99.1M
Q2 24
$164.5M
$97.9M
Net Profit
NEO
NEO
TCBK
TCBK
Q1 26
$-108.0M
Q4 25
$33.6M
Q3 25
$-27.1M
$34.0M
Q2 25
$-45.1M
$27.5M
Q1 25
$-25.9M
$26.4M
Q4 24
$29.0M
Q3 24
$-17.7M
$29.1M
Q2 24
$-18.6M
$29.0M
Gross Margin
NEO
NEO
TCBK
TCBK
Q1 26
43.3%
Q4 25
43.8%
Q3 25
42.8%
Q2 25
42.6%
Q1 25
43.6%
Q4 24
44.9%
Q3 24
44.6%
Q2 24
44.1%
Operating Margin
NEO
NEO
TCBK
TCBK
Q1 26
46.9%
Q4 25
-7.1%
42.6%
Q3 25
-14.4%
43.2%
Q2 25
-26.3%
36.5%
Q1 25
-16.6%
35.8%
Q4 24
-10.7%
38.7%
Q3 24
-12.6%
39.8%
Q2 24
-13.3%
40.0%
Net Margin
NEO
NEO
TCBK
TCBK
Q1 26
-57.9%
Q4 25
251.6%
Q3 25
-14.4%
31.6%
Q2 25
-24.9%
26.6%
Q1 25
-15.4%
26.7%
Q4 24
221.4%
Q3 24
-10.5%
29.3%
Q2 24
-11.3%
29.7%
EPS (diluted)
NEO
NEO
TCBK
TCBK
Q1 26
$-0.13
Q4 25
$1.02
Q3 25
$1.04
Q2 25
$0.84
Q1 25
$0.80
Q4 24
$0.88
Q3 24
$0.88
Q2 24
$0.87

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEO
NEO
TCBK
TCBK
Cash + ST InvestmentsLiquidity on hand
$146.1M
$157.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$828.8M
$1.3B
Total Assets
$1.3B
$9.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEO
NEO
TCBK
TCBK
Q1 26
$146.1M
Q4 25
$159.6M
$157.0M
Q3 25
$164.1M
$298.8M
Q2 25
$154.7M
$314.3M
Q1 25
$346.2M
$308.3M
Q4 24
$367.0M
$145.0M
Q3 24
$362.0M
$320.1M
Q2 24
$355.1M
$206.6M
Total Debt
NEO
NEO
TCBK
TCBK
Q1 26
Q4 25
$341.9M
Q3 25
Q2 25
Q1 25
Q4 24
$541.1M
Q3 24
Q2 24
Stockholders' Equity
NEO
NEO
TCBK
TCBK
Q1 26
$828.8M
Q4 25
$836.6M
$1.3B
Q3 25
$838.3M
$1.3B
Q2 25
$854.0M
$1.3B
Q1 25
$888.3M
$1.3B
Q4 24
$902.3M
$1.2B
Q3 24
$908.2M
$1.2B
Q2 24
$915.9M
$1.2B
Total Assets
NEO
NEO
TCBK
TCBK
Q1 26
$1.3B
Q4 25
$1.4B
$9.8B
Q3 25
$1.4B
$9.9B
Q2 25
$1.4B
$9.9B
Q1 25
$1.6B
$9.8B
Q4 24
$1.6B
$9.7B
Q3 24
$1.6B
$9.8B
Q2 24
$1.6B
$9.7B
Debt / Equity
NEO
NEO
TCBK
TCBK
Q1 26
Q4 25
0.41×
Q3 25
Q2 25
Q1 25
Q4 24
0.60×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEO
NEO
TCBK
TCBK
Operating Cash FlowLast quarter
$-8.1M
$133.3M
Free Cash FlowOCF − Capex
$127.9M
FCF MarginFCF / Revenue
116.9%
Capex IntensityCapex / Revenue
4.9%
Cash ConversionOCF / Net Profit
3.96×
TTM Free Cash FlowTrailing 4 quarters
$222.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEO
NEO
TCBK
TCBK
Q1 26
$-8.1M
Q4 25
$1.3M
$133.3M
Q3 25
$8.9M
$45.1M
Q2 25
$20.3M
$29.2M
Q1 25
$-25.3M
$24.5M
Q4 24
$9.8M
$109.7M
Q3 24
$9.2M
$28.6M
Q2 24
$13.9M
$31.8M
Free Cash Flow
NEO
NEO
TCBK
TCBK
Q1 26
Q4 25
$-6.5M
$127.9M
Q3 25
$570.0K
$43.2M
Q2 25
$14.0M
$28.2M
Q1 25
$-29.8M
$22.8M
Q4 24
$-1.8M
$105.2M
Q3 24
$-1.6M
$27.3M
Q2 24
$814.0K
$30.8M
FCF Margin
NEO
NEO
TCBK
TCBK
Q1 26
Q4 25
-3.4%
116.9%
Q3 25
0.3%
40.2%
Q2 25
7.7%
27.2%
Q1 25
-17.8%
23.1%
Q4 24
-1.0%
104.8%
Q3 24
-0.9%
27.6%
Q2 24
0.5%
31.5%
Capex Intensity
NEO
NEO
TCBK
TCBK
Q1 26
Q4 25
4.1%
4.9%
Q3 25
4.4%
1.7%
Q2 25
3.5%
1.0%
Q1 25
2.7%
1.7%
Q4 24
6.7%
4.5%
Q3 24
6.4%
1.3%
Q2 24
8.0%
1.0%
Cash Conversion
NEO
NEO
TCBK
TCBK
Q1 26
Q4 25
3.96×
Q3 25
1.33×
Q2 25
1.06×
Q1 25
0.93×
Q4 24
3.78×
Q3 24
0.98×
Q2 24
1.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons